Learn how major industry trends are influencing the future of biopharma, including patent expiration challenges, evolving regulatory pathways, and emerging therapeutic targets that are attracting significant investment and attention.
Pharma’s $500B Patent Problem Will Come in Waves – Not a Cliff
Source: PharmaVoice
A wave of patent expirations is expected to put more than $500 billion in global prescription drug sales at risk between 2026 and 2032, prompting many pharmaceutical companies to accelerate business development and M&A. Rather than a single “patent cliff,” the industry is facing a multi-year period of market disruption that will test pipeline strength, lifecycle management strategies, and long-term growth planning.
5 Key Facts About The FDA Expedited IND Pilot Program
Source: PharmaVoice
The FDA’s new Expedited IND Pilot Program aims to accelerate the path from early-stage clinical research to first-in-human trials by providing sponsors with earlier feedback and closer collaboration with qualified research institutions. As part of HHS’s Operation TrialBlazer initiative, the program seeks to improve development efficiency and strengthen the United States’ competitiveness in early-stage clinical research.
3 Drug Targets Pharma Is Betting On Next
Source: PharmaVoice
The FDA plans to strengthen oversight of foreign clinical trial sites as China’s research activity continues to grow. The agency will expand inspections, work with sponsors earlier to assess data provenance and access, strengthen internal reviewer training, and scrutinize studies where data integrity or participant protections cannot be verified.
